148 related articles for article (PubMed ID: 33309877)
1. A chemical-specific adjustment factor for human interindividual differences in kinetics for glutamates (E620-625).
Rietjens IM; Tanaka T; Masuzawa Y; Nakamura H; Ishizaka Y; Teoh KN
Food Chem Toxicol; 2021 Jan; 147():111910. PubMed ID: 33309877
[TBL] [Abstract][Full Text] [Related]
2. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts.
Zu K; Pizzurro DM; Lewandowski TA; Goodman JE
Regul Toxicol Pharmacol; 2017 Oct; 89():83-94. PubMed ID: 28720346
[TBL] [Abstract][Full Text] [Related]
4. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets.
Poulin P; Arnett R
Regul Toxicol Pharmacol; 2017 Dec; 91():142-150. PubMed ID: 29107009
[TBL] [Abstract][Full Text] [Related]
5. Risk Assessment Paradigm for Glutamate.
Roberts A; Lynch B; Rietjens IMCM
Ann Nutr Metab; 2018; 73 Suppl 5(Suppl 5):53-64. PubMed ID: 30508819
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.
Al-Subeihi AA; Alhusainy W; Kiwamoto R; Spenkelink B; van Bladeren PJ; Rietjens IM; Punt A
Toxicol Appl Pharmacol; 2015 Mar; 283(2):117-26. PubMed ID: 25549870
[TBL] [Abstract][Full Text] [Related]
7. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.
Bhat VS; Meek MEB; Valcke M; English C; Boobis A; Brown R
Crit Rev Toxicol; 2017 Oct; 47(9):729-749. PubMed ID: 28681680
[TBL] [Abstract][Full Text] [Related]
8. Derivation of a chemical-specific adjustment factor (CSAF) for use in the assessment of risk from chronic exposure to ethylene glycol: application of International Programme for Chemical Safety guidelines.
Palmer RB; Brent J
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):576-84. PubMed ID: 15990139
[TBL] [Abstract][Full Text] [Related]
9. Introduction and Summary of the 2018 Dietary Glutamate Workshop.
Cynober L; Fernstrom JD; Koletzko B; Rietjens IMCM; Roberts A; Tennant DR; Tomé D; Vorhees CV
Ann Nutr Metab; 2018; 73 Suppl 5():1-4. PubMed ID: 30508812
[TBL] [Abstract][Full Text] [Related]
10. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
11. Advances in assessing ingredient safety.
Dourson ML; York RG
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 2():S112-8. PubMed ID: 27427210
[TBL] [Abstract][Full Text] [Related]
12. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
[TBL] [Abstract][Full Text] [Related]
13. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of glutamic acid (E 620), sodium glutamate (E 621), potassium glutamate (E 622), calcium glutamate (E 623), ammonium glutamate (E 624) and magnesium glutamate (E 625) as food additives.
; Mortensen A; Aguilar F; Crebelli R; Di Domenico A; Dusemund B; Frutos MJ; Galtier P; Gott D; Gundert-Remy U; Leblanc JC; Lindtner O; Moldeus P; Mosesso P; Parent-Massin D; Oskarsson A; Stankovic I; Waalkens-Berendsen I; Woutersen RA; Wright M; Younes M; Boon P; Chrysafidis D; Gürtler R; Tobback P; Altieri A; Rincon AM; Lambré C
EFSA J; 2017 Jul; 15(7):e04910. PubMed ID: 32625571
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling.
Punt A; Jeurissen SM; Boersma MG; Delatour T; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
Toxicol Sci; 2010 Feb; 113(2):337-48. PubMed ID: 19920071
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.
Valcke M; Krishnan K
J Appl Toxicol; 2014 Mar; 34(3):227-40. PubMed ID: 24038072
[TBL] [Abstract][Full Text] [Related]
17. Considerations for deriving a safe intake of propylene glycol.
Lewis AS; Boomhower SR; Marsh CM; Jack MM
Food Chem Toxicol; 2024 Apr; 186():114460. PubMed ID: 38325632
[TBL] [Abstract][Full Text] [Related]
18. Glutamate: A Safe Nutrient, Not Just a Simple Additive.
Loï C; Cynober L
Ann Nutr Metab; 2022; 78(3):133-146. PubMed ID: 35172302
[TBL] [Abstract][Full Text] [Related]
19. Monosodium glutamate metabolism in the neonatal pig: effect of load on plasma, brain, muscle and spinal fluid free amino acid levels.
Stegink LD; Filer LJ; Baker GL
J Nutr; 1973 Aug; 103(8):1138-45. PubMed ID: 4719725
[No Abstract] [Full Text] [Related]
20. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
